Literature DB >> 15582294

The inoculum effect: fact or artifact?

William A Craig, Sujata M Bhavnani, Paul G Ambrose.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15582294     DOI： 10.1016/j.diagmicrobio.2004.07.006

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


× No keyword cloud information.
  19 in total

1.  Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Authors:  Patrick J Gavin; Mira T Suseno; Richard B Thomson; J Michael Gaydos; Carl L Pierson; Diane C Halstead; Jaber Aslanzadeh; Stephen Brecher; Coleman Rotstein; Stephen E Brossette; Lance R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Functional relationship between bacterial cell density and the efficacy of antibiotics.

Authors:  Klas I Udekwu; Nicholas Parrish; Peter Ankomah; Fernando Baquero; Bruce R Levin
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

3.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

4.  Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.

Authors:  F Docobo-Pérez; L López-Cerero; R López-Rojas; P Egea; J Domínguez-Herrera; J Rodríguez-Baño; A Pascual; J Pachón
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

5.  Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria.

Authors:  Vincent H Tam; Henrietta Abodakpi; Weiqun Wang; Kimberly R Ledesma; Paul R Merlau; Katrina Chan; Rachel Altman; Truc T Tran; Michael Nikolaou; Amelia K Sofjan
Journal:  J Antimicrob Chemother       Date:  2021-01-01       Impact factor: 5.790

Review 6.  Collective antibiotic tolerance: mechanisms, dynamics and intervention.

Authors:  Hannah R Meredith; Jaydeep K Srimani; Anna J Lee; Allison J Lopatkin; Lingchong You
Journal:  Nat Chem Biol       Date:  2015-02-17       Impact factor: 15.040

7.  Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Rachel L Soon; Justin R Lenhard; Zackery P Bulman; Patricia N Holden; Pamela Kelchlin; Judith N Steenbergen; Lawrence V Friedrich; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

8.  In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus.

Authors:  Vincent H Tam; Kai-Tai Chang; Zhen Yang; Joseph Newman; Ming Hu
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

10.  Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.

Authors:  C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.